BioStock: Abliva starts late-stage study with KL1333

Lund-based biotech Abliva’s main goal for 2022 was to initiate clinical phase II studies with lead drug candidate KL1333. The company hit their target last week with the initiation of the FALCON study, a study designed with the potential to support registration of the drug for commercialisation. BioStock interviewed Abliva CEO Ellen Donnelly to learn more about this important study.

Read the article at biostock.se:

https://www.biostock.se/en/2022/12/abliva-starts-late-stage-study-with-kl1333/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/